Carmel Chan

About Carmel Chan

Cancer pharmacologist with expertise in pre-clinical and translational cancer research spanning small molecules, antibodies, immune cell therapies and development of oncology preclinical models. Extensive experience in in vitro/ex vivo cell-based assays, in vivo pharmacology and molecular imaging strategies for early drug discovery and elucidation of the mechanisms of action and resistance of drug candidates. Mechanisms of action (MOA) and resistance (MOR): Investigation of MOA and MOR for small molecules, antibodies and immune cell therapiesDrug development: Cell-based high-throughput (HTS) screening of targeted small molecules inhibitors; advancement of CAR-T, CAR-NK, adoptive T cells and DC Vax immunotherapies candidatesIn vivo disease models: Expertise in development and validation of models (xenografts and orthotopic) in syngeneic, transgenic and immunocompromised mice for oncology Assays development: Cellular and biomedical assays for drug discovery, and evaluation of cytotoxicity and persistence of drug productsMolecular imaging: Pioneering in multi-modality imaging (bioluminescence, fluorescence, intravital microscopy, PET/CT) to interrogate biological events for monitoring cell trafficking, therapy responses and immune rejectionScientific communications: Strong record of research productivity with 29 high quality, peer-reviewed publications and 2 published patents.

Experience

1. Consultant

   Endra Life Sciences Nasdaq Ndra

   Apr 2023 — Present

Education

• Stanford University School of Medicine

  Postdoctoral Fellowship

• Irell & Manella Graduate School of Biological Sciences

  Ph.D., Drug Resistance in Breast Cancer

• The University of British Columbia

  B.Sc. (Honors), Cell & Developmental Biology

Skills

• High Throughput Screening
• Transfection
• Cell Based Assays
• Cancer Research
• Cell Biology
• Molecular Imaging
• In Vitro
• Animal Models
• Drug Discovery
• Molecular Biology
• Pharmacology
• Cell Culture
• Cancer
• In Vivo
• Western Blotting